CosmoGodino

Interventional Cardiologist/Cardiologo San Raffaele/
Transcatheter interventions/Outcomes researcher/
Proud father/ As Roma fan

[CosmoGodino @GodinoCosmo]

https://t.co/HdEbYnrGkf

[CosmoGodino @GodinoCosmo]

Il 25 Gennaio 2025 sii terrà presso L'NH Hotel CityLife il primo SINT, meeting cardiologico che promuove il concetto di SINERGISMO tra terapia medica e procedure interventistiche. Vi aspetto
https://t.co/54Kj6WEcHP

[Azeem Latib @azeemlatib]

Great work @jcecharte and @AndreaScotti21. I’m very proud of both you. Thanks for putting a spotlight on the differences in diversity regarding valvular disease.

@MontefioreNYC @MontefioreNYC @EinsteinMed @crfheart

[CosmoGodino @GodinoCosmo]

@GreggWStone The "historic" concepts already demonstrated years ago by IVUS in PCI with stent are confirmed!

[CosmoGodino @GodinoCosmo]

Not so strange!

[JACC Journals @JACCJournals]

#AHA24: How does the benefit of microaxial flow pumps in cardiogenic shock vary by age? In a new analysis of the DanGer Shock trial, Dr. Jacob Møller & team at @CardResearchOuh find that these devices may not benefit older patients (>77 y/o) https://t.co/Qh90qSBgLZ

#JACC #cvGeri #STEMI

[Rodrigo Estévez @RodrigoEstvez1]

New data for Spanish registry suggesting “the less residual TR, the better” after TTEER. Changing concepts ⁦@icruzgonzalez⁩ ⁦@jcecharte⁩ ⁦@PCRonline⁩ ⁦@shci_sec⁩ ⁦@MPAOSS⁩ ⁦@belcid7⁩ #TreatTR https://t.co/S6sg0rT5kt

[Benjamin Hibbert @benhibbertMDPhD]

#TCT2024 Is it time to get rid of cause specific hospitalization as an endpoint?

2 trials showing TAVR reduces CV hosp (EARLY TAVR) and unplanned aortic hospitalization (EVOLVED) with the former hitting a primary composite driving by this cause specific endpoint.

[Denisa Muraru @denisamuraru]

First prospective study at Johns Hopkins on >1000 pts w/ #echofirst and #RHC data to define grades of severity of echo-based measures of RV dysfunction in PH population @CircImaging
https://t.co/IRN2jG73bh

Few learning points:
❗️degree of RV dysfx -> worse outcome & symptoms
❗️echo thresholds to define mild/moderate/severe RV dysfx in PH patients based on percentiles are now available
❗️FAC, RVFWLS, and RVGLS were independently associated with outcomes, whereas TAPSE was not
❗️TAPSE remained normal except when PVR≥7 WU, and even then, was only mildly reduced (1.6±0.4 cm)
❗️RVGLS <20% in PH pts increased mortality risk
❗️TAPSE/PASP and FAC/PASP decreased with increasing PVR
❗️moderately vs mildly decreased TAPSE/PASP has a 37% increased risk of death

Congratulations, @MMukherjeeMD

@LunaGargani @Ivan_Echocardio @lpbadano @NAjmoneMarsan @leylaelifsade @DonalErwan @VDelgadoGarcia @CaravitaSergio @hahn_rt @robertomlang

[JACC Journals @JACCJournals]

Not every #TMVR requires contrast CT. #JACCIMG novel approach to neo-LVOT assessment by #echofirst pre-TMVR TEE: neo-LVOT area &amp; #LVOT gradients had no significant bias compared to #YesCCT. https://t.co/3vlYdcTIZl

@hahn_rt @FabienPraz @joan_bartc

[EAPCIPresident @EAPCIPresident]

The #EAPCI Core Curriculum for Percutaneous Valvular &amp; Structural Heart Intervention

Published in @EuroInterventio on the occasion of #ESCCongress 2024

Significant work from the #EAPCI Training &amp; Certification Committee and collaborators.

https://t.co/ZngWhmV2y4

[Ignacio Cruz Gonzalez @icruzgonzalez]

New insights into #LAAO post-procedural treatment.
✅ Simplified protocols for high-risk bleeding patients?
✅ Outstanding collaborative effort from several Spanish centers.
@pjantunez @RodrigoEstvez1 @freixa_xavier @ignamatsant @shci_sec @scardiosal @Serlotes

[JACC Journals @JACCJournals]

Lower plasma ferritin levels are linked to an increased risk of heart failure &amp; diastolic dysfunction in older adults, regardless of anemia status. Iron repletion could be key in preventing heart failure. https://t.co/X53t58Rcdj

#JACCHF #HeartFailure #ARIC #Anemia

[EuroIntervention @EuroInterventio]

In a large population of up to 1,000 US and European patients with intermediate- and high-risk pulmonary embolism, mechanical thrombectomy using the FlowTriever System was evaluated without a specified comparison group. The study demonstrated a favourable safety profile, with major adverse events in 1.8% of patients, and low all-cause mortality rates at 48 hours (0.3%) and 30 days (0.8%). Significant improvements were noted in haemodynamics and dyspnoea, and a majority of patients avoided overnight ICU stay post-procedure, over the course of 48 hours and 30 days following the intervention. #EIJBestOf https://t.co/oKuRZ5xQvC

[DrPatWJyg @w_jyg]

Do you know the stent #edge is not always at the #marker !

@BotPci @PCRonline @APSIC6 @GruentzigG @mirvatalasnag @mmamas1973 @dimitri_zappi @mornei2011 @jedicath @ANazmiCalik @LAzzaliniMD @sbrugaletta @KardiologieHH @MGtberg @SVRaoMD @Tesslagra @uziyahya46 @jl35wilsonMD

[Philippe Pibarot @PPibarot]

The use of DOACs after TMVR, compared with VKAs, appears to reduce the risk of bleeding complications and decrease the length of hospital stay for patients, without a significant increase in the risk of thrombotic events.
https://t.co/QPeoOFhpUa

[Philippe Pibarot @PPibarot]

After mitral valve repair, women have a higher risk for all-cause mortality at lower LVESD and LVESDi and higher EF. We should consider sex-specific thresholds for LVESDi in surgical decision making in patients with severe MR. https://t.co/l1XknT3ZSS

[Gennaro Giustino, MD @g_giustinoMD]

Optimization of valve expansion for TMVR. Degenerated 27mm Magna w sev stenosis, pre-fractured with 28mm 🎈. 29mm S3 implanted, further post-dilated on atrial side to improve expansion. No post gradient, no leak. Paced OTW. Sentinel captured calcific debries. CT neo-LVOT 321.

[Dr Roxana Mehran @Drroxmehran]

DAPAglofazin Safe in AMI pts without DM, important metabolic benefits for these patients
@AHAScience #AHA23 @American_Heart
Dr. Stefan James Presenting:
THE WINS are in favor of DAPA

[CosmoGodino @GodinoCosmo]

@GreggWStone The mysteries of scientific commissions!

[Gregg W. Stone MD @GreggWStone]

Following a pos ad board, FDA just approved renal denervation with the Recor ultrasound energy-based Paradise system. No word yet on the Medtronic radiofrequency energy-based Spyral system which received a neg ad board review. From our recent JACC editorial results looks similar.